Marshall Roy Posner

Marshall Roy Posner's AcademicInfluence.com Rankings

Marshall Roy Posner

Philosophy

#8961

World Rank

#12448

Historical Rank

Logic

#5966

World Rank

#7432

Historical Rank

philosophy Degrees

Download Badge

Philosophy

Marshall Roy Posner's Degrees

Doctorate Medicine University of Pennsylvania

Why Is Marshall Roy Posner Influential?

(Suggest an Edit or Addition)

(See a Problem?)

Marshall Roy Posner's Published Works

Number of citations in a given year to any of this author's works

Total number of citations to an author for the works they published in a given year. This highlights publication of the most important work(s) by the author

Published Works

Cisplatin and fluorouracil alone or with docetaxel in head and neck cancer. (2007) (1535)
Human neutralizing monoclonal antibodies of the IgG1 subtype protect against mucosal simian–human immunodeficiency virus infection (2000) (924)
Induction chemotherapy followed by concurrent chemoradiotherapy (sequential chemoradiotherapy) versus concurrent chemoradiotherapy alone in locally advanced head and neck cancer (PARADIGM): a randomised phase 3 trial. (2013) (567)
American Society of Clinical Oncology clinical practice guideline for the use of larynx-preservation strategies in the treatment of laryngeal cancer. (2006) (454)
Treatment of pemphigus vulgaris with rituximab and intravenous immune globulin. (2006) (442)
Survival and human papillomavirus in oropharynx cancer in TAX 324: a subset analysis from an international phase III trial. (2011) (437)
The salivary microbiota as a diagnostic indicator of oral cancer: A descriptive, non-randomized study of cancer-free and oral squamous cell carcinoma subjects (2005) (402)
Structural Basis of Immune Evasion at the Site of CD4 Attachment on HIV-1 gp120 (2009) (307)
Racial Survival Disparity in Head and Neck Cancer Results from Low Prevalence of Human Papillomavirus Infection in Black Oropharyngeal Cancer Patients (2009) (297)
Human papillomavirus type 16 and squamous cell carcinoma of the head and neck. (2002) (292)
Taxane-cisplatin-fluorouracil as induction chemotherapy in locally advanced head and neck cancers: an individual patient data meta-analysis of the meta-analysis of chemotherapy in head and neck cancer group. (2013) (266)
Lack of association of alcohol and tobacco with HPV16-associated head and neck cancer. (2007) (263)
Head and neck cancers. (2011) (262)
An IgG human monoclonal antibody that reacts with HIV-1/GP120, inhibits virus binding to cells, and neutralizes infection. (1991) (261)
Inactivation of the Fanconi anemia/BRCA pathway in lung and oral cancers: implications for treatment and survival (2004) (240)
Docetaxel: an active drug for squamous cell carcinoma of the head and neck. (1996) (240)
Functional and immunologic characterization of human immunodeficiency virus type 1 envelope glycoproteins containing deletions of the major variable regions (1993) (233)
An analysis of induction and adjuvant chemotherapy in the multidisciplinary treatment of squamous-cell carcinoma of the head and neck. (1987) (229)
Dose to larynx predicts for swallowing complications after intensity-modulated radiotherapy. (2008) (224)
Characterization of a discontinuous human immunodeficiency virus type 1 gp120 epitope recognized by a broadly reactive neutralizing human monoclonal antibody (1991) (221)
Herceptin in patients with advanced or metastatic salivary gland carcinomas. A phase II study. (2003) (216)
Patterns of gene promoter methylation in squamous cell cancer of the head and neck (2002) (211)
Radiation treatment breaks and ulcerative mucositis in head and neck cancer. (2008) (191)
HER2 Expression in Salivary Gland Carcinomas (2004) (183)
Neoadjuvant therapy for unresectable pancreatic adenocarcinoma. (1993) (178)
2',3'-didehydro-3'-deoxythymidine (d4T) in patients with AIDS or AIDS-related complex: a phase I trial. (1993) (172)
Postnatal Passive Immunization of Neonatal Macaques with a Triple Combination of Human Monoclonal Antibodies against Oral Simian-Human Immunodeficiency Virus Challenge (2001) (169)
Swallowing dysfunction after chemoradiation for advanced squamous cell carcinoma of the head and neck (2004) (161)
Multicenter phase I-II trial of docetaxel, cisplatin, and fluorouracil induction chemotherapy for patients with locally advanced squamous cell cancer of the head and neck. (2001) (157)
Trastuzumab for the treatment of salivary duct carcinoma. (2013) (150)
Oral human papillomavirus (HPV) infection in HPV-positive patients with oropharyngeal cancer and their partners. (2014) (148)
In situ immunologic characterization of cellular constituents in lymph nodes and spleens involved by Hodgkin's disease. (1982) (139)
Pericardial disease in patients with cancer. The differentiation of malignant from idiopathic and radiation-induced pericarditis. (1981) (138)
Sequential therapy for the locally advanced larynx and hypopharynx cancer subgroup in TAX 324: survival, surgery, and organ preservation. (2009) (138)
Neutralization of HIV-1 by F105, a human monoclonal antibody to the CD4 binding site of gp120. (1993) (135)
Human papillomavirus 16 and head and neck squamous cell carcinoma (2007) (129)
Cyclophosphamide, doxorubicin, and cisplatin combination chemotherapy for advanced carcinomas of salivary gland origin (1987) (128)
Phase II trial of docetaxel, cisplatin, fluorouracil, and leucovorin as induction for squamous cell carcinoma of the head and neck. (1999) (126)
Characterization of the Opsonic and Protective Activity against Staphylococcus aureus of Fully Human Monoclonal Antibodies Specific for the Bacterial Surface Polysaccharide Poly-N-Acetylglucosamine (2006) (118)
Induction chemotherapy with docetaxel, cisplatin, fluorouracil, and leucovorin for squamous cell carcinoma of the head and neck: a phase I/II trial. (1998) (117)
Epigenetic profiling reveals etiologically distinct patterns of DNA methylation in head and neck squamous cell carcinoma. (2009) (113)
Relationship of the human immunodeficiency virus type 1 gp120 third variable loop to a component of the CD4 binding site in the fourth conserved region (1992) (112)
Phase I study of gefitinib plus celecoxib in recurrent or metastatic squamous cell carcinoma of the head and neck. (2005) (107)
Salivary gland tumors treated with adjuvant intensity-modulated radiotherapy with or without concurrent chemotherapy. (2012) (106)
Selective chemoembolization in the management of hepatic metastases in refractory colorectal carcinoma (1997) (105)
Docetaxel, cisplatin, and 5‐fluorouracil‐based induction chemotherapy in patients with locally advanced squamous cell carcinoma of the head and neck (2003) (100)
Positron emission tomography with 18F‐fluorodeoxyglucose to predict pathologic response after induction chemotherapy and definitive chemoradiotherapy in head and neck cancer (2004) (95)
Gene expression changes in peripheral blood cells provide insight into the biological mechanisms associated with regimen-related toxicities in patients being treated for head and neck cancers. (2007) (94)
The role of inflammation in head and neck cancer. (2014) (93)
Incidence of hypothyroidism following multimodality treatment for advanced squamous cell cancer of the head and neck (1984) (89)
Chemoradiotherapy-induced upregulation of PD-1 antagonizes immunity to HPV-related oropharyngeal cancer. (2014) (88)
Pharmacokinetic and toxicity evaluation of five-day continuous infusion versus intermittent bolus cis-diamminedichloroplatinum(II) in head and neck cancer patients. (1988) (88)
Cevimeline for the treatment of postirradiation xerostomia in patients with head and neck cancer. (2007) (87)
Hypothyroidism incidence after multimodality treatment for stage III and IV squamous cell carcinomas of the head and neck. (2001) (86)
Dysphagia after Sequential Chemoradiation Therapy for Advanced Head and Neck Cancer (2006) (86)
Synergistic Neutralization of Simian-Human Immunodeficiency Virus SHIV-vpu+ by Triple and Quadruple Combinations of Human Monoclonal Antibodies and High-Titer Anti-Human Immunodeficiency Virus Type 1 Immunoglobulins (1998) (85)
Mechanism of the inhibitory effect of curdlan sulfate on HIV-1 infection in vitro. (1994) (85)
Prognostic Implication of Persistent Human Papillomavirus Type 16 DNA Detection in Oral Rinses for Human Papillomavirus-Related Oropharyngeal Carcinoma. (2015) (83)
Randomized phase 2 study of concomitant chemoradiotherapy using weekly carboplatin/paclitaxel with or without daily subcutaneous amifostine in patients with locally advanced head and neck cancer (2009) (82)
Induction chemotherapy in locally advanced squamous cell carcinoma of the head and neck: role, controversy, and future directions (2018) (81)
Efficacy and toxicity of reirradiation using intensity‐modulated radiotherapy for recurrent or second primary head and neck cancer (2010) (79)
Examining the need for neck dissection in the era of chemoradiation therapy for advanced head and neck cancer. (2006) (78)
Therapeutic Immune Modulation against Solid Cancers with Intratumoral Poly-ICLC: A Pilot Trial (2018) (78)
Functional and molecular characterization of human monoclonal antibody reactive with the immunodominant region of HIV type 1 glycoprotein 41. (1998) (78)
Induction chemotherapy in locally advanced squamous cell cancer of the head and neck: evolution of the sequential treatment approach. (2004) (75)
Cost‐effectiveness of transoral robotic surgery versus (chemo)radiotherapy for early T classification oropharyngeal carcinoma: A cost‐utility analysis (2016) (75)
Resistance to neutralization by broadly reactive antibodies to the human immunodeficiency virus type 1 gp120 glycoprotein conferred by a gp41 amino acid change (1994) (71)
Treatment of advanced squamous cell carcinoma of the head and neck with cisplatin, bleomycin, and methotrexate (PBM). (1981) (70)
Association of Marijuana Smoking with Oropharyngeal and Oral Tongue Cancers: Pooled Analysis from the INHANCE Consortium (2013) (69)
The use of serologic tumor markers in gastrointestinal malignancies. (1994) (67)
Adjusting for patient selection suggests the addition of docetaxel to 5-fluorouracil–cisplatin induction therapy may offer survival benefit in squamous cell cancer of the head and neck (2004) (67)
Human Monoclonal Antibodies to Pseudomonas aeruginosa Alginate That Protect against Infection by Both Mucoid and Nonmucoid Strains1 (2004) (66)
Serum antibodies to the HPV16 proteome as biomarkers for head and neck cancer (2011) (66)
The construction and use of a human-mouse myeloma analogue suitable for the routine production of hybridomas secreting human monoclonal antibodies. (1987) (66)
beta-Tubulin-II expression strongly predicts outcome in patients receiving induction chemotherapy for locally advanced squamous carcinoma of the head and neck: a companion analysis of the TAX 324 trial. (2009) (64)
Paradigm shift in the treatment of head and neck cancer: the role of neoadjuvant chemotherapy. (2005) (64)
Rituximab: a monoclonal antibody to CD20 used in the treatment of pemphigus vulgaris. (2006) (63)
Induction therapy in the modern era of combined-modality therapy for locally advanced head and neck cancer. (2008) (63)
Synergistic neutralization of a chimeric SIV/HIV type 1 virus with combinations of human anti-HIV type 1 envelope monoclonal antibodies or hyperimmune globulins. (1997) (63)
Endoscopic Management of Hypopharyngeal Stenosis after Organ Sparing Therapy for Head and Neck Cancer (2004) (62)
Treatment of oral cavity squamous cell carcinoma with adjuvant or definitive intensity-modulated radiation therapy. (2011) (62)
Concurrent cis-platinum and radiation with or without surgery for advanced head and neck cancer. (1994) (62)
An enzyme-linked immunosorbent assay (ELISA) for the detection of monoclonal antibodies to cell surface antigens on viable cells. (1982) (61)
V3-specific neutralizing antibodies in sera from HIV-1 gp160-immunized volunteers block virus fusion and act synergistically with human monoclonal antibody to the conformation-dependent CD4 binding site of gp120. NIH-NIAID AIDS Vaccine Clinical Trials Network. (1993) (61)
Chemoradiotherapy for Adenoid Cystic Carcinoma: Preliminary Results of an Organ Sparing Approach (2006) (59)
Lymphoid subpopulations of peripheral blood and spleen in untreated Hodgkin's disease (1981) (59)
Induction chemotherapy with cisplatin, fluorouracil, and high-dose leucovorin for squamous cell carcinoma of the head and neck: long-term results. (1997) (59)
Conformational changes in env oligomer induced by an antibody dependent on the V3 loop base (2003) (59)
Hypermethylation of E‐cadherin is an independent predictor of improved survival in head and neck squamous cell carcinoma (2008) (58)
Surface membrane-expressed CD40 is present on tumor cells from squamous cell cancer of the head and neck in vitro and in vivo and regulates cell growth in tumor cell lines. (1999) (58)
The role of induction chemotherapy in the curative treatment of squamous cell cancer of the head and neck. (2000) (58)
Early detection of recurrent disease by FDG-PET/CT leads to management changes in patients with squamous cell cancer of the head and neck. (2013) (57)
A Phase I/II trial of concurrent docetaxel and radiation after induction chemotherapy in patients with poor prognosis squamous cell carcinoma of the head and neck (2002) (57)
Docetaxel, cisplatin, 5-fluorouracil (TPF)-based induction chemotherapy for head and neck cancer and the case for sequential, combined-modality treatment. (2003) (57)
A phase I dose escalation study of epidermal growth factor receptor (EGFR) tyrosine kinase (TK) inhibitor CP-358,774 in patients (pts) with advanced solid tumors (2000) (57)
Phase I study of C-TPF in patients with locally advanced squamous cell carcinoma of the head and neck. (2009) (56)
Potent neutralization of primary human immunodeficiency virus clade C isolates with a synergistic combination of human monoclonal antibodies raised against clade B. (2001) (56)
Serum concentrations of interleukin-8, vascular endothelial growth factor, and epidermal growth factor receptor in patients with squamous cell cancer of the head and neck. (2005) (56)
Phase I study of a human monoclonal antibody directed against the CD4-binding site of HIV type 1 glycoprotein 120. (1998) (56)
Epstein‐Barr virus‐specific adoptive immunotherapy for recurrent, metastatic nasopharyngeal carcinoma (2017) (56)
Vertical Transmission of HIV-1. Correlation with maternal viral load and plasma levels of CD4 binding site anti-gp120 antibodies. (1995) (55)
Phase I/II Trial of Outpatient Docetaxel, Cisplatin, 5-Fluorouracil, Leucovorin (opTPFL) as Induction for Squamous Cell Carcinoma of the Head and Neck (SCCHN) (2002) (55)
Cisplatin administered as a continuous 5-day infusion: plasma platinum levels and urine platinum excretion. (1986) (55)
Patient‐reported receipt of and interest in smoking‐cessation interventions after a diagnosis of cancer (2011) (55)
Functional activity of an HIV-1 neutralizing IgG human monoclonal antibody: ADCC and complement-mediated lysis. (1992) (55)
Phase I dose-finding study of paclitaxel with panitumumab, carboplatin and intensity-modulated radiotherapy in patients with locally advanced squamous cell cancer of the head and neck. (2010) (54)
Hyperphosphatemia in multiple myeloma due to a phosphate‐binding immunoglobulin (1991) (53)
A personalized platform identifies trametinib plus zoledronate for a patient with KRAS-mutant metastatic colorectal cancer (2019) (53)
A randomized phase II study of docetaxel with or without vandetanib in recurrent or metastatic squamous cell carcinoma of head and neck (SCCHN). (2013) (53)
Genetic variation in the vitamin C transporter, SLC23A2, modifies the risk of HPV16-associated head and neck cancer. (2009) (52)
Cell lines and peripheral blood leukocytes derived from individuals with chronic myelogenous leukemia display virtually identical proteins phosphorylated on tyrosine residues. (1987) (52)
Decreased EBNA-1-specific CD8+ T cells in patients with Epstein–Barr virus-associated nasopharyngeal carcinoma (2009) (52)
Postnatal pre‐ and postexposure passive immunization strategies: protection of neonatal macaques against oral simian–human immunodeficiency virus challenge (2002) (51)
Shared VH1-46 gene usage by pemphigus vulgaris autoantibodies indicates common humoral immune responses among patients (2014) (51)
Docetaxel in head and neck cancer: a review. (1998) (51)
HPV16 antibodies as risk factors for oropharyngeal cancer and their association with tumor HPV and smoking status. (2015) (51)
Protection of neonatal macaques against experimental SHIV infection by human neutralizing monoclonal antibodies. (2001) (51)
Cyclopamine increases the cytotoxic effects of paclitaxel and radiation but not cisplatin and gemcitabine in Hedgehog expressing pancreatic cancer cells (2006) (50)
Human Papilloma Virus Specific Immunogenicity and Dysfunction of CD8+ T Cells in Head and Neck Cancer. (2018) (49)
Pathogenic human monoclonal antibody against desmoglein 3. (2006) (49)
Treatment complications after sequential combination chemotherapy and radiotherapy with or without surgery in previously untreated squamous cell carcinoma of the head and neck. (1985) (49)
Chemotherapy of advanced salivary gland neoplasms (1982) (49)
HPV Serum Antibodies as Predictors of Survival and Disease Progression in Patients with HPV-Positive Squamous Cell Carcinoma of the Oropharynx (2015) (49)
Erythropoietin to treat anaemia in patients with head and neck cancer (2004) (48)
Organ Preservation and Treatment Toxicity With Induction Chemotherapy Followed by Radiation Therapy or Chemoradiation for Advanced Laryngeal Cancer (2005) (47)
Efficacy and toxicity of chemoradiotherapy using intensity-modulated radiotherapy for unknown primary of head and neck. (2011) (47)
Relationship between radiation treatment time and overall survival after induction chemotherapy for locally advanced head-and-neck carcinoma: a subset analysis of TAX 324. (2011) (47)
Human papillomavirus 6 seropositivity is associated with risk of head and neck squamous cell carcinoma, independent of tobacco and alcohol use. (2009) (46)
Characterization of the cDNA of a broadly reactive neutralizing human anti-gp120 monoclonal antibody. (1992) (46)
Preoperative chemotherapy and radiation therapy for stage IIIa carcinoma of the lung. (1992) (45)
Human monoclonal antibodies to the V3 loop of HIV-1 gp120 mediate variable and distinct effects on binding and viral neutralization by a human monoclonal antibody to the CD4 binding site. (1993) (45)
Cooperativity of neutralizing antibodies directed against the V3 and CD4 binding regions of the human immunodeficiency virus gp120 envelope glycoprotein. (1992) (45)
Genetic and Epigenetic Somatic Alterations in Head and Neck Squamous Cell Carcinomas Are Globally Coordinated but Not Locally Targeted (2010) (44)
Head and neck squamous cell carcinoma: new translational therapies. (2010) (44)
Binding and neutralization activity of human IgG1 and IgG3 from serum of HIV-infected individuals. (2003) (43)
An initial experience using concurrent paclitaxel and radiation in the treatment of head and neck malignancies. (1999) (43)
Preferences and utilities for health states after treatment for oropharyngeal cancer: Transoral robotic surgery versus definitive (chemo)radiotherapy (2014) (42)
A Phase II Clinical and Pharmacodynamic Study of E7070 in Patients with Metastatic, Recurrent, or Refractory Squamous Cell Carcinoma of the Head and Neck (2004) (42)
Docetaxel induction therapy in locally advanced squamous cell carcinoma of the head and neck (2003) (42)
The PARADIGM trial: A phase III study comparing sequential therapy (ST) to concurrent chemoradiotherapy (CRT) in locally advanced head and neck cancer (LANHC). (2012) (42)
Interactions of human antibodies, epitope exposure, antibody binding and neutralization of primary isolate HIV-1 virions (2002) (41)
Cetuximab and radiotherapy for head and neck cancer. (2006) (40)
Development of specific monoclonal antibodies and a sensitive discriminatory immunoassay for the circulating tumor markers SCCA1 and SCCA2. (2000) (40)
Human papillomavirus and oropharyngeal squamous cell carcinoma: what the clinician should know (2013) (39)
HPV16 transmission between a couple with HPV-related head and neck cancer. (2008) (39)
Radiographic extracapsular extension and treatment outcomes in locally advanced oropharyngeal carcinoma (2014) (38)
A phase I trial of continuous infusion cisplatin (1987) (38)
Polymerase chain reaction detection of HPV in squamous carcinoma of the oropharynx. (2010) (38)
Identification of a new neutralizing epitope conformationally affected by the attachment of CD4 to gp120. (1993) (38)
Synergistic inhibition of HIV-1 by CD4 binding domain reagents and V3-directed monoclonal antibodies. (1993) (38)
Passive immunization against oral AIDS virus transmission: An approach to prevent mother‐to‐infant HIV‐1 transmission? (2001) (36)
TGFβ receptor 1: an immune susceptibility gene in HPV-associated cancer. (2014) (36)
A Genotype-Phenotype Examination of Cyclin D1 on Risk and Outcome of Squamous Cell Carcinoma of the Head and Neck (2008) (36)
The Neutralization Properties of a HIV-Specific Antibody Are Markedly Altered by Glycosylation Events Outside the Antigen-Binding Domain1 (2007) (36)
Combined antegrade and retrograde esophageal dilation for head and neck cancer‐related complete esophageal stenosis (2010) (35)
Circulating lymphocyte populations in Hodgkin's disease after mantle and paraaortic irradiation. (1983) (35)
Effect of antibody valency on interaction with cell-surface expressed HIV-1 and viral neutralization. (1994) (34)
Phase I study of continuous-infusion cisplatin. (1986) (34)
Evidence of determinant spreading in the antibody responses to prostate cell surface antigens in patients immunized with prostate-specific antigen. (2002) (34)
Acupuncture for Dysphagia After Chemoradiation Therapy in Head and Neck Cancer: A Case Series Report (2010) (33)
Biologic predictors of serologic responses to HPV in oropharyngeal cancer: The HOTSPOT study. (2015) (33)
Androgen receptor immunohistochemistry on paraffin-embedded tissue. (1994) (33)
Influence of heavy chain constant regions on antigen binding and HIV-1 neutralization by a human monoclonal antibody. (1995) (32)
A Bispecific Antibody Composed of a Nonneutralizing Antibody to the gp41 Immunodominant Region and an Anti-CD89 Antibody Directs Broad Human Immunodeficiency Virus Destruction by Neutrophils (2008) (32)
Structure of the Fab Fragment of F105, a Broadly Reactive Anti-Human Immunodeficiency Virus (HIV) Antibody That Recognizes the CD4 Binding Site of HIV Type 1 gp120 (2005) (32)
Therapeutic targeting of regulatory T cells enhances tumor-specific CD8+ T cell responses in Epstein-Barr virus associated nasopharyngeal carcinoma. (2013) (32)
Generation of monoclonal antibodies against phosphotyrosine and their use for affinity purification of phosphotyrosine-containing proteins. (1991) (32)
Loss of serum antibodies to a conformational epitope of HIV-1/gp120 identified by a human monoclonal antibody is associated with disease progression. (1993) (31)
Concurrent weekly docetaxel and concomitant boost radiation therapy in the treatment of locally advanced squamous cell cancer of the head and neck. (2006) (31)
Cost utility of docetaxel as induction chemotherapy followed by chemoradiation in locally advanced squamous cell carcinoma of the head and neck (2009) (29)
Phase II study of induction chemotherapy with paclitaxel, ifosfamide, and carboplatin (TIC) for patients with locally advanced squamous cell carcinoma of the head and neck (2003) (29)
Novel biomarker panel predicts prognosis in human papillomavirus‐negative oropharyngeal cancer (2012) (28)
Effects of 1 alpha, 25-dihydroxyvitamin D3 on the human chronic myelogenous leukemia cell line RWLeu-4. (1990) (28)
A phase II trial of palliative docetaxel plus 5-fluorouracil for squamous-cell cancer of the head and neck. (2000) (28)
High‐dose intravenous zidovudine with 5‐fluorouracil and leucovorin. A phase I trial (1992) (27)
Combined modality treatment of head and neck cancer with cisplatin, bleomycin, methotrexate‐leucovorin chemotherapy (1985) (27)
Expression and functional activity of isotype and subclass switched human monoclonal antibody reactive with the base of the V3 loop of HIV-1 gp120. (2003) (27)
Combined modality therapy for stage IIIA non-small cell carcinoma of the lung. (1993) (27)
In vitro effects of anti-HIV immunotoxins directed against multiple epitopes on HIV type 1 envelope glycoprotein 160. (1996) (26)
Prognostic significance of Kadish staging in esthesioneuroblastoma: An analysis of the National Cancer Database (2017) (26)
Human papillomavirus (HPV) 16 antibodies at diagnosis of HPV-related oropharyngeal cancer and antibody trajectories after treatment. (2017) (26)
Pharmacologic evaluation of megestrol acetate oral suspension in cachectic AIDS patients. (1994) (26)
Human antibody variable region gene usage in HIV-1 infection. (1996) (25)
Evolving strategies for combined-modality therapy for locally advanced head and neck cancer. (2007) (25)
Evaluating the Utility and Prevalence of HPV Biomarkers in Oral Rinses and Serology for HPV-related Oropharyngeal Cancer (2019) (25)
Combination of monalizumab and cetuximab in recurrent or metastatic head and neck cancer patients previously treated with platinum-based chemotherapy and PD-(L)1 inhibitors. (2020) (24)
Rate of pathologic complete responses to docetaxel, cisplatin, and fluorouracil induction chemotherapy in patients with squamous cell carcinoma of the head and neck. (2006) (24)
Extracapsular extension is associated with worse distant control and progression-free survival in patients with lymph node-positive human papillomavirus-related oropharyngeal carcinoma. (2017) (24)
A Pilot Surrogate Endpoint Biomarker Study of Celecoxib in Oral Premalignant Lesions (2008) (24)
Acupuncture for dysphagia after chemoradiation in head and neck cancer: rationale and design of a randomized, sham-controlled trial. (2012) (24)
Induction chemotherapy in locally advanced head and neck cancer: a new standard of care? (2008) (23)
Lymphocytes cytotoxic to uveal and skin melanoma cells from peripheral blood of ocular melanoma patients (1991) (23)
Pharmacokinetics of F105, a human monoclonal antibody, in persons infected with human immunodeficiency virus type 1 (1996) (23)
The syndrome of inappropriate antidiuretic hormone secretion associated with induction chemotherapy for squamous cell carcinoma of the head and neck (1986) (22)
Differentiation-induced changes in protein-tyrosine phosphatase activity and commensurate expression of CD45 in human leukemia cell lines. (1992) (22)
Docetaxel in squamous cell cancer of the head and neck. (2001) (22)
Advanced squamous carcinoma of the head and neck. A preliminary report of neoadjuvant chemotherapy with cisplatin, bleomycin, and methotrexate. (1984) (22)
Minimal Incidence of Serum Antibodies Reactive with Intact Primary Isolate Virions in Human Immunodeficiency Virus Type 1-Infected Individuals (1999) (21)
Human-human hybrids secreting pneumococcal antibodies. (1984) (21)
Oral zidovudine, continuous-infusion fluorouracil, and oral leucovorin calcium: a phase I study. (1990) (21)
T‐cell lymphoblastic lymphoma with subsequent acute nonlymphocytic leukemia. A case report (1982) (21)
Native HIV type 1 virion surface structures: relationships between antibody binding and neutralization or lessons from the viral capture assay. (2004) (21)
Small cell carcinomas of the larynx: Results of combined modality treatments (1983) (20)
A phase II study of everolimus in patients with aggressive RAI refractory (RAIR) thyroid cancer (TC). (2013) (20)
Prognostic value of radiographic extracapsular extension in locally advanced head and neck squamous cell cancers. (2014) (20)
Chemotherapy and radiotherapy in locally advanced head and neck cancer: an individual patient data network meta-analysis. (2021) (19)
Pathogenicity and Epitope Characteristics Do Not Differ in IgG Subclass-Switched Anti-Desmoglein 3 IgG1 and IgG4 Autoantibodies in Pemphigus Vulgaris (2016) (19)
De-Escalated Adjuvant Therapy after Transoral Robotic Surgery for Human Papillomavirus-Related Oropharyngeal Carcinoma: The Sinai Robotic Surgery (SIRS) Trial. (2021) (19)
Phase II randomized study of concomitant chemoradiation using weekly carboplatin/paclitaxel with or without daily subcutaneous amifostine in patients with newly diagnosed locally advanced squamous cell carcinoma of the head and neck. (2003) (18)
Integration of chemotherapy in the curative treatment of locally advanced head and neck cancer (2003) (18)
The role of HPV status in recurrent/metastatic squamous cell carcinoma of the head and neck. (2014) (18)
Novel agents for the treatment of mucositis. (2007) (18)
Acupuncture for Chemoradiation Therapy-Related Dysphagia in Head and Neck Cancer: A Pilot Randomized Sham-Controlled Trial. (2016) (18)
Taxanes in cancer of the head and neck (2014) (17)
Integrating systemic agents into multimodality treatment of locally advanced head and neck cancer. (2010) (17)
Oropharynx cancer (OPC) in TAX 324: Human papillomavirus (HPV) and survival. (2010) (17)
Phase Ib study of dovitinib in combination with gemcitabine plus cisplatin or gemcitabine plus carboplatin in patients with advanced solid tumors (2014) (16)
CD40 function in squamous cell cancer of the head and neck. (2005) (16)
Treatment of oropharyngeal squamous cell carcinoma with IMRT: patterns of failure after concurrent chemoradiotherapy and sequential therapy. (2012) (16)
Characterization of a vitamin D3-resistant human chronic myelogenous leukemia cell line. (1994) (16)
Impact of obesity on outcomes for patients with head and neck cancer. (2018) (16)
Organ preservation for adenoid cystic carcinoma of the larynx. (2013) (16)
A phase II study of combined oral uracil and ftorafur with leucovorin for patients with squamous cell carcinoma of the head and neck (2001) (16)
Phase I study of panitumumab + chemoradiotherapy (CRT) for head and neck cancer (HNC) (2008) (16)
Results of a phase II study evaluating monalizumab in combination with cetuximab in previously treated recurrent or metastatic squamous cell carcinoma of the head and neck (R/M SCCHN). (2018) (16)
Phase I study of panitumumab, chemotherapy and intensity-modulated radiotherapy (IMRT) for head and neck cancer (HNC): Early results (2007) (16)
Palliative chemotherapy in patients with salivary gland neoplasms and preliminary reports of 2 recent phase II studies with trastuzumab and gemcitabine. (2003) (15)
Human immunoglobulin production in immunodeficient mice: enhancement by immunosuppression of host and in vitro activation of human mononuclear cells (1992) (15)
High-Dose Intravenous Zidovudine with 5-Fluorouracil and Leucovorin (1992) (15)
Seeking alternative biological therapies: the future of targeted molecular treatment. (2009) (15)
Continuous-infusion cisplatin and bolus 5-fluorouracil in colorectal carcinoma. (1987) (14)
Cetuximab added to docetaxel, cisplatin, 5-fluorouracil Induction chemotherapy (C-TPF) in patients with newly diagnosed locally advanced head and neck cancer: A phase I study (2008) (14)
Long term survival with adjuvant carboplatin, paclitaxel, and radiation therapy in anaplastic thyroid cancer. (2005) (14)
Human monoclonal antibodies reactive with human myelomonocytic leukemia cells. (1989) (13)
Toxicity of aggressive multimodality therapy including cisplatinum, bleomycin and methotrexate with radiation and/or surgery for advanced head and neck cancer. (1982) (13)
A Drosophila platform identifies a novel, personalized therapy for a patient with adenoid cystic carcinoma (2021) (13)
Tolerability, Toxicity, and Temporal Implications of Transoral Robotic Surgery (TORS) on Adjuvant Radiation Therapy in Carcinoma of the Head and Neck (2014) (13)
Adjuvant Therapy for Salivary Gland Carcinomas. (2016) (13)
Induction chemotherapy in head and neck cancer. (2009) (12)
The generation of hybridomas secreting human monoclonal antibodies reactive with type II collagen. (1989) (12)
Influence of multimodality therapy on the management of pancreas carcinoma. (1993) (12)
Adjuvant Radiation Therapy Alone for HPV Related Oropharyngeal Cancers with High Risk Features (2016) (12)
Comparison of immune repertoires of Chinese and Philippine patients infected with Schistosoma japonicum (1991) (12)
Standard of care vs reduced-dose chemoradiation after induction chemotherapy in HPV+ oropharyngeal carcinoma patients. (2017) (12)
Pre-diagnostic dynamic HPV16 IgG seropositivity and risk of oropharyngeal cancer. (2017) (12)
Clinical Outcomes in Patients with Recurrent or Metastatic Human Papilloma Virus-positive Head and Neck Cancer. (2016) (11)
The PARADIGM trial: A phase III study comparing sequential therapy (ST) to concurrent chemoradiotherapy (CRT) in locally advanced head and neck cancer (LAHNC): Preliminary toxicity report. (2010) (11)
Recent advances in combined modality therapy for locally advanced head and neck cancer. (2007) (11)
31st Annual Meeting and Associated Programs of the Society for Immunotherapy of Cancer (SITC 2016): part two (2016) (11)
Surveillance Imaging in HPV-related Oropharyngeal Cancer. (2018) (11)
Phase I trial and pharmacokinetics of escalating doses of paclitaxel and concurrent hyperfractionated radiotherapy with or without amifostine in patients with advanced head and neck carcinoma (2005) (10)
The prognostic impact of human papillomavirus status following treatment failure in oropharyngeal cancer (2017) (10)
Dose to the Larynx Predicts for Swallowing Complications Following IMRT and Chemotherapy (2007) (10)
POSITRON EMISSION TOMOGRAPHY WITH 18 F-FLUORODEOXYGLUCOSE TO PREDICT PATHOLOGIC RESPONSE AFTER INDUCTION CHEMOTHERAPY AND DEFINITIVE CHEMORADIOTHERAPY IN HEAD AND NECK CANCER (2004) (10)
Abstract CT158: Phase II study of monalizumab, a first-in-class NKG2A monoclonal antibody, in combination with cetuximab in previously treated recurrent or metastatic squamous cell carcinoma of the head and neck (R/M SCCHN): Preliminary assessment of safety and efficacy (2018) (9)
Novel approach to construction of human "myeloma analogues" for production of human monoclonal antibodies. (1983) (9)
The prognostic significance of human papilloma virus in sinonasal squamous cell carcinoma (2020) (9)
Squamous cell carcinoma of the oral tongue in two patients previously exposed to long-term pegylated liposomal doxorubicin. (2012) (9)
Phase I study of gefitinib plus celecoxib in patients with metastatic and/or locally recurrent squamous cell carcinoma of the head and neck (SCCHN) (2004) (9)
Real-time PCR HPV genotyping in fine needle aspirations of metastatic head and neck squamous cell carcinoma: Exposing the limitations of conventional p16 immunostaining. (2019) (9)
A human anti-HIV autoantibody enhances EBV transformation and HIV infection. (1999) (8)
Oral HPV infection in HPV-positive oropharyngeal cancer cases and their spouses. (2013) (8)
Abstract LB-095: HPV E7 antigen-expressing Listeria-based immunotherapy (ADXS11-001) prior to robotic surgery for HPV-positive oropharyngeal cancer enhances HPV-specific T cell immunity (2016) (8)
Role of Prophylactic Bilateral Tonsillectomy as a Cancer Preventive Strategy (2015) (8)
Trimodality therapy for oropharyngeal cancer in the TORS era: Is there a cohort that may benefit? (2019) (8)
Simple enzyme immunoassay for titration of antibodies to the CD4-binding site of human immunodeficiency virus type 1 gp120 (1995) (8)
Epstein Barr virus transformation of peripheral blood B cells secreting antibodies reactive with cell surface antigens. (1990) (8)
Overcoming the Constraints of Anti-HIV/CD89 Bispecific Antibodies That Limit Viral Inhibition (2016) (8)
Role of Chemotherapy in the Multidisciplinary Approach to Advanced Head and Neck Cancer: Potentials and Problems (1981) (8)
A new face of the HPV epidemic: Oropharyngeal cancer in the elderly. (2020) (8)
TAXANE-CISPLATIN-5FU AS INDUCTION CHEMOTHERAPY IN LOCALLY ADVANCED HEAD AND NECK SQUAMOUS CELL CARCINOMA: AN INDIVIDUAL PATIENT DATA META-ANALYSIS OF THE MACH-NC GROUP (2011) (8)
Human monoclonal antibodies reactive with cell surface antigens on human leukemia cell lines: many antibodies are (auto)antibodies. (1990) (8)
Redefining risk of contralateral cervical nodal disease in early stage oropharyngeal cancer in the human papillomavirus era (2021) (8)
Controversies and role of HPV16 in recurrent/metastatic squamous cell cancers of the head and neck. (2014) (7)
Long-term results from TAX324: A phase III trial of sequential therapy comparing TPF to PF in locally advanced (LA) squamous cell cancer of the head and neck (HNC). (2010) (7)
A Phase 1 Study of Afatinib in Combination with Postoperative Radiation Therapy with and Without Weekly Docetaxel in Intermediate- and High-Risk Patients with Resected Squamous Cell Carcinoma of the Head and Neck. (2019) (7)
Plasma pharmacokinetics and biological activity of a human immunodeficiency virus type 1 neutralizing human monoclonal antibody, F105, in cynomolgus monkeys. (1994) (7)
Treatment tolerability and outcomes in elderly patients with head and neck cancer (2020) (7)
Targeting EGFR in head and neck cancer: a decade of progress (2009) (7)
First report of the safety/tolerability and preliminary antitumor activity of HB-201 and HB-202, an arenavirus-based cancer immunotherapy, in patients with HPV16+ cancers. (2021) (6)
Human single-chain antibodies inhibit replication of human immunodeficiency virus type 1 (HIV-1). (2005) (6)
A phase I study of the safety and immunogenicity of a multipeptide personalized genomic vaccine in the adjuvant treatment of solid cancers. (2017) (6)
Progress and perspectives in chemoprevention of head and neck cancer (2003) (6)
Racial disparities in incidence of human papillomavirus-associated oropharyngeal cancer in an urban population. (2016) (6)
Role of human papillomavirus and p16 staining in a patient with head and neck cancer presenting with a synchronous lung nodule: a case report and review of the literature. (2015) (6)
An IgG human monoclonal antibody reactive with a surface membrane antigen expressed on malignant breast cancer cells. (1991) (6)
Phase I study of gefitinib plus celecoxib in patients with metastatic and/or locally recurrent squamous cell carcinoma of the head and neck (SCCHN). (2004) (6)
Assessment and management of mucositis in head and neck cancer patients (2012) (5)
Does response to induction chemotherapy (IC) predict locoregional control after concurrent chemoradiotherapy (CCRT) in locally advanced head and neck cancer (LAHNC)? (2014) (5)
Efficacy of multimodality therapy in gastric adenocarcinoma. (1993) (5)
Treatment of oropharyngeal squamous cell carcinoma with IMRT: patterns of failure after concurrent chemoradiotherapy and sequential therapy. (2012) (5)
Impact of combined modality therapy on the treatment of adenocarcinoma of the colon. (1993) (5)
Phase 2 study of dalantercept in recurrent or metastatic squamous cell carcinoma of the head and neck. (2014) (5)
Integrating novel agents into the curative treatment of head and neck cancer (2006) (5)
Prospective Phase II Trial of PFL-Induction Chemotherapy Followed by Definitive Local Treatment for Advanced Squamous Cell Carcinoma of the Head and Neck: 10-Year Follow-up (2004) (4)
Adjuvant treatment of colorectal adenocarcinoma. (1993) (4)
Landscape of oncoviral genotype and co-infection via human papilloma and hepatitis B viral tumor in situ profiling (2021) (4)
AGenotype-Phenotype Examination of Cyclin D 1 on Risk and Outcome of Squamous Cell Carcinoma of the Head and Neck (2008) (4)
Guideline for the Use of Larynx-Preservation Strategies in the Treatment of Laryngeal Cancer (2006) (4)
Dichotomy in cross‐clade reactivity and neutralization by HIV‐1 sera: Implications for active and passive immunotherapy (2005) (4)
Combined modality treatment of head and neck cancer with cisplatin, bleomycin, methotrexate-leucovorin chemotherapy. (1986) (4)
Emerging drugs for head and neck cancer (2006) (4)
A Phase I‐II Trial of Continuous‐Infusion Cisplatin, Continuous‐Infusion 5‐Fluorouracil, and VP‐16 in Colorectal Carcinoma (1990) (4)
Adjuvant post-operative chemoradiotherapy in head and neck cancer: a standard of care? (2005) (4)
Human Papillomavirus Type 16 and Squamous Cell Carcinoma of the Head and Neck 1 (2002) (4)
The SPECTRUM of findings in treatment options for recurrent/metastatic head and neck cancer. (2013) (4)
Two phase III clinical studies of cevimeline for post-radiation xerostomia in patients with head and neck cancer (2005) (4)
Sequential therapy for locally advanced larynx and hypopharynx cancer: Subgroup analysis from the TAX 324 Study (2008) (4)
Transgenic drosophila as a drug-screening platform in colorectal cancer and medullary thyroid cancer. (2016) (3)
Long‐term outcomes in patients with recurrent human papillomavirus‐positive oropharyngeal cancer after upfront transoral robotic surgery (2020) (3)
Clinical pharmacokinetics of 3-day continuous infusion cisplatin and daily bolus 5-Fluorouracil (2004) (3)
Induction chemotherapy in the management of squamous cell cancer of the head and neck. (1997) (3)
O28. Randomized phase II study of concomitant chemoradiation using weekly carboplatin/paclitaxel/concomitant boost radiation with or without daily subcutaneous amifostine in patients with newly diagnosed locally advanced head and neck cancer (2009) (3)
Rate of complete pathological responses (pCR) to docetaxel/cisplatin/5-fluorouracil (TPF) induction chemotherapy in patients with newly diagnosed, locally advanced squamous cell carcinoma of the head and neck (SCCHN) (2005) (3)
A phase I/II study of docetaxel (D) and concomitant boost radiation (CBR) for patients with squamous cell cancer of the head and neck (SCCHN) following induction chemotherapy (IC). (2004) (3)
A Phase I/II Trial of 5‐Fluorouracil and Etoposide in Metastatic Colorectal Carcinoma (1989) (3)
Racial Disparities in Incidence of Human Papillomavirus–Associated Oropharyngeal Cancer in an Urban Population (2014) (3)
Salivary Gland Tumors Treated with Adjuvant Intensity Modulated Radiation with or without Concurrent Chemotherapy: A Recent Experience (2010) (2)
In situ, therapeutic vaccination against refractory solid cancers with intratumoral Poly-ICLC: A phase I study. (2016) (2)
Epstein-Barr virus (EBV)-specific immunotherapy in nasopharygneal carcinoma (NPC). (2009) (2)
Acupuncture for dysphagia after chemoradiation therapy in head and neck cancer: A randomized sham-controlled study. (2013) (2)
Window of opportunity trial of HPV E7 antigen-expressing Listeria-based therapeutic vaccination prior to robotic surgery for HPV-positive oropharyngeal cancer. (2015) (2)
Relationship between Radiation Treatment Parameters and Overall Survival following Induction Chemotherapy in a Sequential Regimen for Locally Advanced Head and Neck Carcinoma (LAHNC): A Subset Analysis of TAX324 (2010) (2)
Liquid phase human papillomavirus genotype analysis of aspirated metastatic head and neck squamous cell carcinoma: Fine needle aspiration supernatant is a rich source of tumor DNA that can increase the diagnostic yield (2020) (2)
The Evolution of Induction Chemotherapy in Locally Advanced Squamous Cell Cancer of the Head and Neck (2005) (2)
The role of chemotherapy for advanced carcinoma of the supraglottic and glottic larynx. (1984) (2)
A phase I study of cabazitaxel in combination with platinum and 5-fluorouracil (PF) in locally advanced squamous cell carcinoma of head and neck (LA-SCCHN). (2017) (2)
Prognostic implication of persistent HPV16 DNA detection in oral rinses for HPV-positive oropharyngeal carcinoma. (2015) (2)
Progression-free survival (PFS) as a measure of efficacy for anti-EGFR antibodies in recurrent/metastatic (R/M) squamous cell carcinoma of head and neck (SCCHN). (2013) (2)
Endothelial growth factor receptor inhibitors in recurrent metastatic cancer of the head and neck (2016) (2)
An immunoregulatory human monoclonal antibody in schistosomiasis japonica. (1991) (2)
Head and neck cancer carcinoma: new directions for treatment. (2002) (2)
HPV and survival in patients with oropharyngeal squamous cell cancer of the head and neck (OPC) treated with induction chemotherapy followed by chemoradiotherapy (ST) versus chemoradiotherapy alone (CRT): The Dana-Farber experience. (2012) (1)
432 Nemvaleukin alfa, a novel engineered IL-2 cytokine, in combination with the anti-PD-1 antibody pembrolizumab in patients with recurrent/metastatic head and neck squamous cell carcinoma (ION-01 study) (2021) (1)
Antigen-Binding Domain by Glycosylation Events Outside the AlteredHIV-Specific Antibody Are Markedly The Neutralization Properties of a (2007) (1)
2440: Re-Irradiation With IMRT for Head and Neck Cancer (2006) (1)
Swallowing function after intensity modulated radiotherapy (IMRT) and chemotherapy for head and neck cancer (2007) (1)
Phase III Study of Cevimeline for Radiation-Induced Xerostomia (2004) (1)
Shared VH1-46 gene usage by anti-desmoglein 3 antibodies in pemphigus vulgaris suggest a common mechanism for developing autoimmunity (BA2P.116) (2014) (1)
Dysphagia Following Sequential Chemoradiation Therapy for Advanced Head and Neck Cancer (2005) (1)
Abstract 5639: Changes in local and peripheral T cell diversity after HPV E7 antigen-expressing Listeria-based immunotherapy (ADXS11-001) prior to robotic surgery for HPV-positive oropharyngeal cancer (2018) (1)
A phase I/II study of HB-201, an arenavirus-based cancer immunotherapy, alone, or in combination with anti-PD-1 in patients with HPV16+ cancers. (2020) (1)
Pilot study of celecoxib in oral premalignant lesions (OPLs): Preliminary results (2005) (1)
Landscape of oncoviral genotype and co-infection via Human papilloma and Hepatitis B viral tumor in-situ profiling (2020) (1)
Effect of early detection of recurrent disease by FDG PET/CT on management of patients with squamous cell cancer of the head and neck (HNSCC). (2013) (1)
81P Monalizumab in combination with cetuximab post platinum and anti-PD-(L)1 in patients with recurrent/metastatic squamous cell carcinoma of the head and neck (R/M SCCHN): Updated results from a phase II trial (2020) (1)
Phase I study of cabazitaxel-PF induction chemotherapy in patients with locally advanced squamous cell carcinoma of the head and neck (SCCHN). (2014) (1)
Phase II study of dalantercept, a novel inhibitor of ALK1-mediated angiogenesis, in patients with recurrent or metastatic squamous cell carcinoma of the head and neck. (2013) (1)
Meaningful Questions in "Organ Preservation" - Past, Present, and Future. (2016) (1)
Abstract 2988: Exploring the association between immune-related genetic variations and virally mediated head and neck cancer (2012) (1)
Human mAbs to Pseudomonas aeruginosa alginate that protect against infection by both mucoid and nonmucoid strains. (2007) (1)
RETROSPECTIVE RESULTS NEED PROSPECTIVE CONFIRMATION. AUTHOR'S REPLIES (1995) (0)
A Bispeciﬁc Antibody Composed of a Nonneutralizing Antibody to the gp41 Immunodominant Region and an Anti-CD89 Antibody Directs Broad Human Immunodeﬁciency Virus Destruction by Neutrophils (cid:1) (2008) (0)
Impact of chemoradiotherapy for locally advanced head and neck cancer on swallowing function (2007) (0)
Detection of antibodies to the HPV16 proteome in head and neck cancer patient sera. (2010) (0)
Interleukin-8 (IL-8) serum levels and squamous cell cancer of the head and neck (SCCHN). (2004) (0)
Abstract 626: Cisplatin-based concurrent chemoradiotherapy antagonizes anti-tumor immunity in patients with HPV-positive oropharyngeal cancer (2014) (0)
RETROSPECTIVE RESULTS NEED PROSPECTIVE CONFIRMATION. AUTHOR'S REPLIES (1995) (0)
Antibody Neutralizing Function of Monoclonal Impact of IgA Constant Domain on HIV-1 (2012) (0)
Effects of analogs of 1,25(OH)2 Vitamin D3 on the proliferation and differentiation of the human chronic myelogenous leukemia cell line, RWLeu-4 (2005) (0)
Human monoclonal antibodies to human leukemias. Initial characterization of specificities and antigens. (1989) (0)
Is Radiographic Extracapsular Extension Prognostic in Human Papillomavirus–Related Oropharyngeal Cancers? (2014) (0)
Human Monoclonal Antibodies Protect Neonatal and Adult Rhesus Monkeys from Mucosal or Parenteral Immunodeficiency Virus Exposure (1999) (0)
(S024) Extracapsular Extension Is Associated With Worse Distant Control and Progression-Free Survival in Patients With Lymph Node-Positive Human Papillomavirus-Related Oropharyngeal Carcinoma (2017) (0)
Erratum: Human mAbs to Pseudomonas aeruginosa alginate that protect against infection by both mucoid and nonmucoid strains (Journal of Immunology (2004) 173 (5671-5678)) (2007) (0)
myelogenous leukemia cell line Characterization of a vitamin D3-resistant human chronic (2010) (0)
Clinical Management of HPV-Related Oropharyngeal Cancer (2015) (0)
Abstract 2130: Human papillomavirus and hepatitis B virus in situ tumor oncoviral genotype and coinfection drive oncogenesis and patient clinical response in cross cancer analysis (2020) (0)
Abstract 4559: Novel T-cell targets for HPV16-associated oropharyngeal cancer immune therapy (2017) (0)
Clinical trials in squamous cell carcinoma of the head and neck. (2012) (0)
Personalized cancer therapy for patients with metastatic medullary thyroid cancer (MTC). (2014) (0)
421 A phase II trial of docetaxel in squamous cell cancer of the head and neck (1995) (0)
Development of a radioimmunoassay to bradykinin using monoclonal antibodies. (1991) (0)
A 49-year-old male with locally advanced squamous cell carcinoma of the head and neck: the case for sequential chemoradiotherapy. (2003) (0)
Nonsurgical treatment of laryngeal cancer. (2004) (0)
2378 : Use Of Peripheral Blood Monocytes (PBM) To Define Changes in Gene Expression Associated With Amifostine Treatment and Their Association With Oral Mucositis (OM) in Patients Being Treated With Chemoradiotherapy for Squamous Cell Carcinoma of the Head and Neck(SCCHN) (2006) (0)
517 LUMINOS-103: a basket trial evaluating the safety and efficacy of PVSRIPO and PVSRIPO in combination with anti-PD-1/L1 checkpoint inhibitors in patients with advanced solid tumors (2021) (0)
Retrospective review of patients treated with intensity modulated radiation therapy (IMRT) with or without concurrent chemotherapy for locally advanced thyroid cancer: The Dana-Farber experience. (2012) (0)
How does TPF improve survival over PF? – Authors' reply (2011) (0)
Panel discussion continued. the role of chemotherapy in treatment of advanced squamous cell cancer of the head and neck (1984) (0)
Abstract 902: Serum antibodies to the HPV16 proteome as biomarkers for head and neck cancer (2011) (0)
Comparison ofImmuneRepertoires ofChinese andPhilippine Patients Infected withSchistosoma japonicum (1991) (0)
Miniseminar: Treatment of T2 and T3 Laryngeal Cancer in 2004: Has the State of the Art Changed? (2004) (0)
Squamous cell carcinoma of the oral cavity (SCCOC) in young patients: The Dana Farber Cancer Institute experience. (2013) (0)
Interdisciplinary case study: from fly-to-bedside, translating basic research to the clinic (2021) (0)
Acupuncture for dysphagia after chemoradiation therapy in head and neck cancer: An ongoing pilot, randomized, sham-controlled trial. (2010) (0)
Clinical outcomes in genetically targeted cancer treatment. (2016) (0)
Winning the Race: A Proactive, Nurse-Managed Treatment Plan for Head and Neck Cancer (2011) (0)
Increased Levels of Mitochondrial DNA in an Etoposide-resistant Human Monocytic Leukaemia Cell Line (THIWE) (1991) (0)
Organ preservation for patients treated with induction chemotherapy (IC) followed by radiation therapy (RT) or chemoradiation (CRT) for advanced stage squamous cell carcinoma of the larynx (SCCL). (2004) (0)
P049) The Prognostic Impact of HPV Status Following Treatment Failure in Oropharyngeal Cancer (2017) (0)
Induction Chemotherapy in Locally Adva nced Head a nd Neck C ancer : AN ew St a ndard of C are? (2008) (0)
289 PGV-001: a phase 1 trial of a personalized neoantigen peptide vaccine for the treatment of malignancies in the adjuvant setting (2020) (0)
Robotic Surgery plus Chemo-Radiation Therapy. (2017) (0)
In response to Dr. Forastiere (1995) (0)
Peptides binding to poly-glucosamine N-acetyl (PNAG / DPNAG) and procedures for use thereof (2005) (0)
Abstract 1566: Association of a serum HPV16 IgG signature and risk of oropharyngeal cancer (2015) (0)
Oncologic Outcomes and Patterns of Failure in Patients Treated with Transoral Robotic Surgery for HPV related Oropharyngeal Squamous Cell Carcinoma (2017) (0)
Crystal structure of HIV-gp120 core in complex with CD4-binding site antibody b13, space group C2221 (2009) (0)
4 – Cancer of the Head and Neck region (2010) (0)
Structure of HIV-1 gp120 (core with V3) in Complex with CD4-Binding-Site Antibody F105 (2009) (0)
mucoid and nonmucoid strains. both alginate that protect against infection by Human mAbs to Pseudomonas aeruginosa (2013) (0)
Time to change the treatment paradigms in anaplastic thyroid carcinoma. (2012) (0)
Field of Classification Search Primary Examiner — (2017) (0)
Long-term symptom burden and orodental health of oropharyngeal cancer (OPC) survivors following treatment with chemoradiotherapy (CRT) or sequential therapy (ST). (2013) (0)
Microenvironment and Immunology TGF b Receptor 1 : An Immune Susceptibility Gene in HPV-Associated Cancer (2014) (0)
Human Monoclonal Antibodies to Pseudomonas aeruginosa Alginate That Protect against Infection by Both Mucoid and Nonmucoid Strains 1 (2004) (0)
196 – Head and Neck Cancer (2012) (0)
Radiographic extracapsular extension (ECE) and treatment outcomes in locally advanced oropharyngeal carcinoma (OPC). (2013) (0)
Alternative Medicine Committee: Dr Mehmet Oz on Maintaining Wellness through Alternative Therapies (2004) (0)
Genomic analysis and personalized cancer therapy for metastatic colorectal cancer. (2015) (0)
Dose reduction to dysphagia/aspiration-related structures (DARS) in patients receiving induction chemotherapy (IC) followed by concurrent chemoradiation therapy (CCRT) for locally advanced squamous cell carcinoma of the head and neck (LASCCHN) (2014) (0)
Abstract B098: Discovering immunotherapeutic T-cell epitopes for HPV16-associated cancers (2016) (0)
Abstract #1428: DNA methylation profiles are associated with specific genome-wide copy number alteration profiles in head and neck squamous cell carcinoma (2009) (0)
Quality of life (QoL) analysis in HPV positive oropharynx cancer (HPVOPC) patients in a randomized deintensification trial. (2018) (0)
Abstract 2007: Concurrent gene promoter hypermethylation and allele loss occurs infrequently in head and neck squamous cell carcinomas (2010) (0)
Concomitant Chemoradiation Using Weekly Carboplatin/Paclitaxel With or Without Daily Subcutaneous Amifostine in the Treatment of Locally Advanced Squamous Cell Carcinoma of the Head and Neck (2005) (0)
Head and neck cancers. (2005) (0)
Quality of Life With Adjuvant Radiation Therapy Following Transoral Robotic Surgery (TORS) for Head-and-Neck Cancer (2012) (0)

This paper list is powered by the following services:

What Schools Are Affiliated With Marshall Roy Posner?

Marshall Roy Posner is affiliated with the following schools: